TP53 and breast cancer: The key mediator of this response was induction of the CDK inhibitor CDKN1A (p21 protein) – a p53 target and mediator of cell cycle arrest and senescence that is also amongst the most strongly upregulated genes in ER+ breast cancer models treated with MDM2i.